Healthcare -
Biotechnology - NASDAQ - CA
$ 1.17
-3.31 %
$ 5.13 M
Market Cap
-0.69
P/E
CASH FLOW STATEMENT
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Clearmind Medicine Inc.
| Net Income | -5.25 M |
| Depreciation & Amortization | 51.1 K |
| Capital Expenditures | 0 |
| Stock-Based Compensation | 884 K |
| Change in Working Capital | -130 K |
| Others | -708 K |
| Free Cash Flow | -4.86 M |
Cash Flow
Millions
| Oct-2024 | Oct-2023 | Oct-2022 | Oct-2021 | Oct-2020 | Oct-2019 | Oct-2018 | Oct-2017 | |
|---|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||||
| Net Income | (5.3) | (6.2) | (9.4) | (3.9) | (0.2) | (0.1) | (0.2) | 6.67 K |
| Depreciation & Amortization | 51.1 K | 41.6 K | 0.1 | 2.57 K | 180 | 0 | 0 | 0 |
| Deferred Income Tax | 0.1 | 17.4 K | 40.8 K | 0 | 0 | 0 | 0 | 0 |
| Stock Based Compensation | 0.9 | 0.4 | 0.9 | 0.5 | 0 | 0 | 0.1 | 0 |
| Other Operating Activities | (0.5) | 0.2 | 0.8 | 0.2 | 28 | 5.35 K | 60 K | 371 |
| Change in Working Capital | (0.1) | (0.7) | 1.7 | 26 K | 31.2 K | 42.3 K | 1.64 K | 2.45 K |
| Cash From Operations | (4.9) | (6.3) | (5.1) | (2.8) | (0.3) | 63 K | (0.1) | 9.12 K |
| INVESTING CASH FLOW | ||||||||
| Capital Expenditures | 0 | 0 | 7.59 K | (0.2) | 10 K | 10 K | (0.1) | 18.4 K |
| Other Items | (0.2) | 26.2 K | 0 | 20 K | 4.9 K | 0 | 0 | 0 |
| Cash From Investing Activities | (0.2) | 26.2 K | 7.59 K | (0.3) | 5.1 K | 10 K | (0.1) | 18.4 K |
| FINANCING CASH FLOW | ||||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 42.6 K | 40.9 K | 96.5 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 4.1 | 0.4 | 698.0 | 0 | (0.4) | 0 | 1.52 K | 0.1 |
| Cash From Financing Activities | 6.3 | 8.4 | 0.7 | 7.4 | 0.6 | 0 | 0.2 | 0.1 |
| CHANGE IN CASH | ||||||||
| Net Change In Cash | 1.1 | 3.8 | (4.4) | 4.3 | 0.3 | 73 K | 28.8 K | 0.1 |
| FREE CASH FLOW | ||||||||
| Free Cash Flow | (4.9) | (6.3) | (5.1) | (3.1) | (0.3) | 73 K | (0.2) | 27.5 K |